NEJM

Janssen and BMS Present Results of Milvexian in P-II AXIOMATIC-TKR Study for the Treatment of TKR Surgery at AHA 2021, Published in NEJM

Shots: The P-II AXIOMATIC-TKR study evaluates the efficacy and safety of milvexian (qd/bid) vs enoxaparin (SC) in 1242 patients with elective TKR surgery The trial met both of its pre-specified proof-of-principle requirements i.e., milvexian (bid) showed significant efficacy, reduction in the risk of postoperative VTE in a dose-dependent manner without increasing the risk of bleeding …

Janssen and BMS Present Results of Milvexian in P-II AXIOMATIC-TKR Study for the Treatment of TKR Surgery at AHA 2021, Published in NEJM Read More »

Regeneron Publishes the Results of REGEN-COV (casirivimab and imdevimab) in P-III Trial for COVID-19 in NEJM

Shots: The P-III trial evaluates the efficacy and safety of REGEN-COV (casirivimab and imdevimab, 1200/2400mg) vs PBO in a non-hospitalized patient with COVID-19 The trial met its 1EPs & 2EPs i.e., 70% reduction in the risk of hospitalization or death in high-risk non-hospitalized patients & the safety profile was consistent with a previously reported data …

Regeneron Publishes the Results of REGEN-COV (casirivimab and imdevimab) in P-III Trial for COVID-19 in NEJM Read More »

AbbVie Publishes 12-week Results of Atogepant in P-III ADVANCE Trial for the Preventive of Migraine in NEJM

Shots: The P-III ADVANCE trial evaluates efficacy, safety & tolerability of atogepant (PO, 10/30/60 mg, qd) vs PBO in 910 patients with EM who experienced 4-14 migraine days/mos. Results: patients achieving a ≥50% reduction in monthly migraine days (55.6%/58.7%/60.8% vs 29.0%) @12wks. & all doses were well tolerated. Additionally, 30/60 mg doses showed improvements in …

AbbVie Publishes 12-week Results of Atogepant in P-III ADVANCE Trial for the Preventive of Migraine in NEJM Read More »

Roche Publishes the Results of Evrysdi (risdiplam) in FIREFISH Study to Treat of Type 1 SMA at NEJM

Shots: The company has reported the results from Part 2 of the FIREFISH study evaluating the efficacy and safety of Evrysdi in 41 infants aged 1-7 mos. with symptomatic Type 1 SMA The study met its 1EP i.e., 29% of infants sitting without support for at least 5 sec., 93% of infants were alive and …

Roche Publishes the Results of Evrysdi (risdiplam) in FIREFISH Study to Treat of Type 1 SMA at NEJM Read More »

Pfizer Presents Results of Tofacitinib in STOP-COVID Study for Patients Hospitalized with COVID-19 Pneumonia at NEJM

Shots: The STOP-COVID study was conducted with a research collaboration b/w Pfizer & an ARO in Brazil, evaluating the efficacy & safety of tofacitinib (10mg, bid) + SoC vs PBO + SoC in a ratio (1:1) in 289 hospitalized patients with COVID-19 pneumonia who were not on ventilation for 14 days or until hospital discharge …

Pfizer Presents Results of Tofacitinib in STOP-COVID Study for Patients Hospitalized with COVID-19 Pneumonia at NEJM Read More »

Do we spend too much on health care?

According to my post yesterday, it may seem like the answer is ‘yes’. The US spends by far the most money per person and the largest share of its economy on health care. While cross-country comparisons often grab the headlines, a New England Journal of Medicine Perspective by Katharine Baicker and Amitabh Chandra argues that …

Do we spend too much on health care? Read More »